Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News CSA Medical’s RejuvenAir System granted CE marking

CSA Medical’s RejuvenAir System granted CE marking

11th December 2019

CSA Medical’s cryosurgical RejuvenAir System, developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Bronchitis (CB), has been granted CE Mark approval on the back of results from a study involving 35 patients who revealed that there were no particular safety issues associated with the system’s procedure, and that their health, wellbeing and general quality of life was considerably better for at least twelve months.

The system works by freezing the damaged surface area lung cells through execution of a bronchoscopic technique which sprays Metered Cryospray of liquid nitrogen at minus one-hundred and ninety-six degrees Celsius, to specific areas in the lungs airways to kick starts the healing process.

CSA Medical’s Senior Vice President of regulatory, clinical and quality affairs, Heather Nigro, stated: “While pharmaceutical options can decrease cough and mucus production, the RejuvenAir System offers the only treatment able to address the underlying cause of CB, while simultaneously treating the debilitating symptoms. This patient population now has an option that can dramatically improve their quality of life, that’s exciting!”

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.